Association Between Mineralocorticoid Receptor Antagonist and Mortality in SARS-CoV-2 Patients: A Systematic Review and Meta-Analysis
March 2022
in “
Healthcare
”
TLDR Mineralocorticoid receptor antagonist therapy does not significantly reduce mortality in COVID-19 patients.
This systematic review and meta-analysis investigated the association between mineralocorticoid receptor antagonist (MRA) therapy and mortality in SARS-CoV-2 patients. The study included five studies with a total of 1,388,178 subjects, of which 80,903 were receiving MRA therapy. Despite the proposed protective effects of MRAs, such as spironolactone, against SARS-CoV-2 infection, the analysis found no significant association between MRA therapy and reduced mortality in these patients (OR = 0.387, 95% CI: 0.134–1.117, p = 0.079).